Status:

UNKNOWN

Superinfection and Hyperinflammatory Phenotype in COVID-19 (Coronavirus Disease 2019) Pneumonia Patients

Lead Sponsor:

Brno University Hospital

Collaborating Sponsors:

Masaryk University

Conditions:

COVID-19 Pneumonia

Superinfection Lung

Eligibility:

All Genders

18-99 years

Brief Summary

Patients suffering from COVID-19 (Coronavirus Disease 2019) pneumonia are prone to bacterial and mycotic superinfection. According to existing evidence, the prevalence of superinfection is about 8% to...

Detailed Description

The inflammatory markers, such as C-reactive protein (CRP), procalcitonin (PCT), presepsin (PSP), interleukin-6 (IL-6) frequently used as diagnostic tools in COVID-19 (Coronavirus Disease 2019), are u...

Eligibility Criteria

Inclusion

  • admission on ICU
  • age more than 18 years
  • COVID-19 pneumonia criteria fulfilled

Exclusion

  • none
  • \-

Key Trial Info

Start Date :

December 21 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2022

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT04867161

Start Date

December 21 2020

End Date

December 31 2022

Last Update

June 30 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital Brno

Brno, Czechia, 62500

Superinfection and Hyperinflammatory Phenotype in COVID-19 (Coronavirus Disease 2019) Pneumonia Patients | DecenTrialz